Valneva Reports Nine Month Results Marked by Further Major Corporate Achievements

Valneva reported today its nine-month financial results ending September 30, 2020.

Q3 milestones included

  • Major COVID-19 vaccine partnership with U.K. government
    • Pre-clinical and industrialization activities on track
  • Positive top-line results for Lyme Phase 2 studies
  • First company to initiate Phase 3 study for chikungunya vaccine; EMA PRIME Designation granted
  • New US military / DoD contract for IXIARO®

Cash position of €156 million at end of Q3, year-end outlook expected to exceed €180 million

Operating financial results impacted by second wave of COVID-19 pandemic

  • Limited product sales in Q3
  • Gross Margin impacted
  • US military orders and supply rephased into Q4

Read more